GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Takara Bio Inc (TSE:4974) » Definitions » Current Ratio

Takara Bio (TSE:4974) Current Ratio : 7.45 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Takara Bio Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Takara Bio's current ratio for the quarter that ended in Dec. 2023 was 7.45.

Takara Bio has a current ratio of 7.45. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Takara Bio's Current Ratio or its related term are showing as below:

TSE:4974' s Current Ratio Range Over the Past 10 Years
Min: 3.27   Med: 6.61   Max: 9.56
Current: 7.45

During the past 13 years, Takara Bio's highest Current Ratio was 9.56. The lowest was 3.27. And the median was 6.61.

TSE:4974's Current Ratio is ranked better than
72.55% of 1552 companies
in the Biotechnology industry
Industry Median: 3.775 vs TSE:4974: 7.45

Takara Bio Current Ratio Historical Data

The historical data trend for Takara Bio's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takara Bio Current Ratio Chart

Takara Bio Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.86 6.14 3.72 3.92 5.40

Takara Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.98 5.40 6.73 6.98 7.45

Competitive Comparison of Takara Bio's Current Ratio

For the Biotechnology subindustry, Takara Bio's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takara Bio's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Takara Bio's Current Ratio distribution charts can be found below:

* The bar in red indicates where Takara Bio's Current Ratio falls into.



Takara Bio Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Takara Bio's Current Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Current Ratio (A: Mar. 2023 )=Total Current Assets (A: Mar. 2023 )/Total Current Liabilities (A: Mar. 2023 )
=77569/14375
=5.40

Takara Bio's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=61947/8317
=7.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takara Bio  (TSE:4974) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Takara Bio Current Ratio Related Terms

Thank you for viewing the detailed overview of Takara Bio's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Takara Bio (TSE:4974) Business Description

Traded in Other Exchanges
Address
Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.

Takara Bio (TSE:4974) Headlines

No Headlines